DE60219292T2 - Pyrazolderivate zur behandlung von hiv - Google Patents

Pyrazolderivate zur behandlung von hiv Download PDF

Info

Publication number
DE60219292T2
DE60219292T2 DE60219292T DE60219292T DE60219292T2 DE 60219292 T2 DE60219292 T2 DE 60219292T2 DE 60219292 T DE60219292 T DE 60219292T DE 60219292 T DE60219292 T DE 60219292T DE 60219292 T2 DE60219292 T2 DE 60219292T2
Authority
DE
Germany
Prior art keywords
pyrazol
methyl
oxy
diethyl
dichlorophenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60219292T
Other languages
German (de)
English (en)
Other versions
DE60219292D1 (de
Inventor
Lyn Howard Pfizer Globa Sandwich JONES
Charles Eric Pfizer Globa Sandwich MOWBRAY
Davis Anthony Pfizer Globa Sandwich PRICE
Matthew Duncan Pfizer Globa Sandwich SELBY
Paul Anthony Pfizer Globa Sandwich STUPPLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0108999A external-priority patent/GB0108999D0/en
Priority claimed from GB0127426A external-priority patent/GB0127426D0/en
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE60219292D1 publication Critical patent/DE60219292D1/de
Application granted granted Critical
Publication of DE60219292T2 publication Critical patent/DE60219292T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60219292T 2001-04-10 2002-04-04 Pyrazolderivate zur behandlung von hiv Expired - Lifetime DE60219292T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0108999 2001-04-10
GB0108999A GB0108999D0 (en) 2001-04-10 2001-04-10 Pyrazole derivatives
GB0127426 2001-11-15
GB0127426A GB0127426D0 (en) 2001-11-15 2001-11-15 Pyrazole derivatives
PCT/IB2002/001234 WO2002085860A1 (en) 2001-04-10 2002-04-04 Pyrazole derivatives for treating hiv

Publications (2)

Publication Number Publication Date
DE60219292D1 DE60219292D1 (de) 2007-05-16
DE60219292T2 true DE60219292T2 (de) 2008-04-10

Family

ID=26245955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219292T Expired - Lifetime DE60219292T2 (de) 2001-04-10 2002-04-04 Pyrazolderivate zur behandlung von hiv

Country Status (42)

Country Link
US (4) US7109228B2 (OSRAM)
EP (2) EP1377556B1 (OSRAM)
JP (1) JP3806090B2 (OSRAM)
KR (1) KR100569324B1 (OSRAM)
CN (1) CN100408564C (OSRAM)
AR (2) AR037319A1 (OSRAM)
AT (2) ATE358669T1 (OSRAM)
AU (1) AU2002242926B2 (OSRAM)
BG (1) BG66349B1 (OSRAM)
BR (1) BRPI0208811B8 (OSRAM)
CA (1) CA2443449C (OSRAM)
CR (1) CR7069A (OSRAM)
CY (2) CY1107626T1 (OSRAM)
CZ (1) CZ305099B6 (OSRAM)
DE (1) DE60219292T2 (OSRAM)
DK (2) DK1377556T3 (OSRAM)
DO (1) DOP2002000378A (OSRAM)
EA (1) EA007184B1 (OSRAM)
EE (1) EE05400B1 (OSRAM)
ES (2) ES2385659T3 (OSRAM)
GE (1) GEP20053619B (OSRAM)
HR (1) HRP20030783B1 (OSRAM)
HU (1) HU229025B1 (OSRAM)
IL (2) IL157875A0 (OSRAM)
IS (1) IS2734B (OSRAM)
MA (1) MA27009A1 (OSRAM)
ME (1) ME00558A (OSRAM)
MX (1) MXPA03009380A (OSRAM)
MY (1) MY146669A (OSRAM)
NO (1) NO326518B1 (OSRAM)
NZ (1) NZ529403A (OSRAM)
OA (1) OA12501A (OSRAM)
PA (1) PA8543601A1 (OSRAM)
PE (1) PE20021056A1 (OSRAM)
PL (3) PL216985B1 (OSRAM)
PT (2) PT1762567E (OSRAM)
RS (1) RS51166B (OSRAM)
SI (2) SI1377556T1 (OSRAM)
SK (1) SK287858B6 (OSRAM)
TW (1) TWI333488B (OSRAM)
UY (1) UY27248A1 (OSRAM)
WO (1) WO2002085860A1 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05400B1 (et) * 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
WO2003057673A1 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
JP4228587B2 (ja) 2002-05-22 2009-02-25 昭和電工株式会社 アミノメチル基含有ベンズアミド化合物の製造方法
US20040132793A1 (en) * 2002-09-16 2004-07-08 Pfizer Inc. Pyrazole derivatives
GB0221477D0 (en) * 2002-09-16 2002-10-23 Pfizer Ltd Chemical compounds
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
CA2554696C (en) 2004-02-13 2009-06-30 Warner-Lambert Company Llc Androgen receptor modulators
EP1737813A1 (en) 2004-04-13 2007-01-03 Warner-Lambert Company LLC Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
AR048650A1 (es) * 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
CA2570047C (en) 2004-07-08 2010-09-28 Warner-Lambert Company Llc 4-cycloalkoxy benzonitriles as androgen modulators
EP1874732A1 (en) 2005-04-20 2008-01-09 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EA014693B1 (ru) * 2005-11-08 2010-12-30 Пфайзер Лимитед Терапевтически активные соединения
ES2566481T3 (es) 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
EP2057125B1 (en) 2006-08-16 2011-03-30 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
US20080096950A1 (en) * 2006-10-19 2008-04-24 Karl Richard Gibson Compounds Useful In Therapy
US9280685B2 (en) * 2006-12-08 2016-03-08 Johnnie R. Jackson System and method for portable medical records
WO2008135824A1 (en) * 2007-05-02 2008-11-13 Pfizer Limited Oxyalkylpyrazole compounds useful in therapy
MX2009013865A (es) 2007-06-22 2010-01-27 Hoffmann La Roche Urea y derivados carbamato como inhibidores no nucleosidicos de la transcriptasa inversa.
US20100249176A1 (en) * 2007-10-24 2010-09-30 Barrow James C Heterocycle amide t-type calcium channel antagonists
CA2701594C (en) 2007-10-24 2014-02-18 Merck Sharp & Dohme Corp. Heterocycle phenyl amide t-type calcium channel antagonists
EP2225239B1 (en) 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
EP2558007A4 (en) * 2010-04-13 2017-11-29 Sentreheart, Inc. Methods and devices for accessing and delivering devices to a heart
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
KR101861883B1 (ko) * 2010-12-06 2018-05-28 글락소 그룹 리미티드 Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물
WO2013050873A1 (en) 2011-10-07 2013-04-11 Phivco Uk Limited Process for the preparation of lersivirine
WO2013050884A1 (en) 2011-10-07 2013-04-11 Phivco Uk Limited Process for the preparation of lersivirine
WO2013057593A1 (en) 2011-10-07 2013-04-25 Phivco Uk Limited Process for the preparation of lersivirine
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
US9695127B2 (en) 2012-11-08 2017-07-04 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating HIV and methods for using the compounds
US10026064B2 (en) 2013-09-13 2018-07-17 Microsoft Technology Licensing, Llc Automatically recommending updates based on stored lifecycle information
WO2015060348A1 (ja) * 2013-10-23 2015-04-30 大日本住友製薬株式会社 縮合ピラゾール誘導体
EP3140289A1 (en) * 2014-05-06 2017-03-15 E. I. du Pont de Nemours and Company Fungicidal pyrazoles
EP3760208B1 (en) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting human satellite ii (hsatii)
JP6626885B2 (ja) * 2014-10-31 2019-12-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新しいピリジニルオキシ及びフェニルオキシピラゾリル化合物
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
JOP20180092A1 (ar) * 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20210213041A1 (en) 2018-02-06 2021-07-15 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
KR102114389B1 (ko) * 2018-05-02 2020-05-25 이화여자대학교 산학협력단 신규 소듐채널 저해 화합물, 이의 제조방법, 및 이를 포함하는 소듐채널 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020056564A1 (zh) 2018-09-17 2020-03-26 南通纺织丝绸产业技术研究院 基于金属氢化物/钯化合物体系制备1,3-二羰基化合物的方法
JP2022504982A (ja) * 2018-10-18 2022-01-13 南京聖和薬業股▲ふん▼有限公司 TGF-βR1阻害剤としての化合物及びその応用
CN113527304B (zh) * 2020-04-17 2025-08-12 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的制备方法
CN113527306B (zh) * 2020-04-17 2025-06-24 南京圣和药物研发有限公司 喹啉类TGF-β1抑制剂的晶型
KR20250023466A (ko) 2022-06-15 2025-02-18 닛산 가가쿠 가부시키가이샤 피라졸 화합물, 그 제조 중간체 및 유해 생물 방제제
EP4692065A1 (en) 2023-03-31 2026-02-11 Nissan Chemical Corporation Pyrazole compound and harmful organism control agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303200A (en) * 1963-11-05 1967-02-07 American Home Prod Pyrazole-1-ethanol derivatives
US3963742A (en) * 1974-07-12 1976-06-15 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as herbicidal agents
US4009277A (en) * 1975-01-17 1977-02-22 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazolium salts as fungicidal agents
US4041046A (en) 1975-06-06 1977-08-09 American Cyanamid Company 1,2-Dialkyl-3,4,5-trisubstituted pyrazole compounds
US4000301A (en) 1975-11-14 1976-12-28 American Cyanamid Company Fungicidal use of 4-alkoxypyrazoles
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH0565237A (ja) 1991-09-10 1993-03-19 Mitsubishi Heavy Ind Ltd メタノールを媒体としたエネルギ供給方法
FR2682379B1 (fr) * 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
WO1994022830A1 (en) 1993-03-31 1994-10-13 Smithkline Beecham Corporation Chemical compounds
FR2707295A1 (fr) 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
DE69408950T2 (de) 1993-12-14 1998-10-15 Mitsubishi Chem Corp N-Pyrazolylcarbamatderivate und Fungizide für Landwirtschaft und Gartenbau, die diese als aktive Bestandteile erhalten, Produktion und Zwischenprodukte
FR2722369B1 (fr) 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
DE69532245T2 (de) * 1994-09-26 2004-09-16 Shionogi & Co., Ltd. Imidazolderivat
TW343232B (en) * 1994-10-13 1998-10-21 Chisso Corp Difluorooxymethane derivative and liquid crystal composition
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
MXPA02010993A (es) * 2000-05-12 2003-03-10 Genzyme Corp Reguladores de transmision de la tnf-alfa.
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
EE05400B1 (et) * 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks

Also Published As

Publication number Publication date
JP2004531535A (ja) 2004-10-14
BR0208811A (pt) 2004-03-09
BRPI0208811B8 (pt) 2021-05-25
DK1377556T3 (da) 2007-07-16
WO2002085860A1 (en) 2002-10-31
EA007184B1 (ru) 2006-08-25
KR100569324B1 (ko) 2006-04-07
CZ305099B6 (cs) 2015-05-06
IL157875A0 (en) 2004-03-28
HK1063781A1 (zh) 2005-01-14
ATE358669T1 (de) 2007-04-15
EP1762567A1 (en) 2007-03-14
SI1762567T1 (sl) 2012-08-31
PL396946A1 (pl) 2012-01-02
US20060020012A1 (en) 2006-01-26
IS6939A (is) 2003-09-04
PL217224B1 (pl) 2014-06-30
AR076259A2 (es) 2011-06-01
NZ529403A (en) 2005-06-24
US8063044B2 (en) 2011-11-22
HUP0303735A3 (en) 2004-07-28
CY1107626T1 (el) 2013-04-18
YU77503A (sh) 2006-05-25
JP3806090B2 (ja) 2006-08-09
AR037319A1 (es) 2004-11-03
RS51166B (sr) 2010-10-31
KR20040007496A (ko) 2004-01-24
CN100408564C (zh) 2008-08-06
CN1514828A (zh) 2004-07-21
NO20034523L (no) 2003-12-09
PE20021056A1 (es) 2002-12-03
MY146669A (en) 2012-09-14
CA2443449A1 (en) 2002-10-31
HRP20030783A2 (en) 2005-08-31
UY27248A1 (es) 2002-11-29
ME00558A (en) 2011-12-20
AU2002242926B2 (en) 2007-10-11
PL398536A1 (pl) 2012-06-04
PL216985B1 (pl) 2014-06-30
US20090215712A1 (en) 2009-08-27
CZ20032676A3 (cs) 2004-11-10
SK287858B6 (sk) 2012-01-04
EP1377556B1 (en) 2007-04-04
OA12501A (en) 2006-05-26
CA2443449C (en) 2008-11-04
EE05400B1 (et) 2011-04-15
US20030100554A1 (en) 2003-05-29
DK1762567T3 (da) 2012-06-25
PL365026A1 (en) 2004-12-27
NO20034523D0 (no) 2003-10-09
EA200300943A1 (ru) 2004-08-26
BG66349B1 (bg) 2013-08-30
BRPI0208811B1 (pt) 2018-03-13
EP1762567B1 (en) 2012-05-02
US20120029192A1 (en) 2012-02-02
CR7069A (es) 2007-12-17
TWI333488B (en) 2010-11-21
ES2385659T3 (es) 2012-07-27
MA27009A1 (fr) 2004-12-20
MXPA03009380A (es) 2004-04-21
PT1762567E (pt) 2012-07-16
NO326518B1 (no) 2008-12-22
US7109228B2 (en) 2006-09-19
PA8543601A1 (es) 2002-10-31
GEP20053619B (en) 2005-09-26
HU229025B1 (en) 2013-07-29
BG108244A (bg) 2005-04-30
EP1377556A1 (en) 2004-01-07
ATE556059T1 (de) 2012-05-15
PT1377556E (pt) 2007-06-06
HUP0303735A2 (hu) 2004-03-01
DOP2002000378A (es) 2002-10-15
US7435728B2 (en) 2008-10-14
DE60219292D1 (de) 2007-05-16
ES2283532T3 (es) 2007-11-01
EE200300497A (et) 2004-02-16
IL157875A (en) 2010-05-17
HRP20030783B1 (hr) 2011-11-30
SI1377556T1 (sl) 2007-08-31
CY1113515T1 (el) 2016-06-22
PL217629B1 (pl) 2014-08-29
SK12442003A3 (sk) 2004-12-01
IS2734B (is) 2011-04-15

Similar Documents

Publication Publication Date Title
US8063044B2 (en) Pyrazole derivatives
DE60121590T2 (de) Pyrazolderivate
KR100441229B1 (ko) 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(cGMP PDE5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논
AU2002242926A1 (en) Pyrazole derivatives for treating HIV
NL1031626C2 (nl) Verbindingen die bruikbaar zijn in therapie.
DE60318874T2 (de) Pyrazolderivate
DE60319254T2 (de) Pyrazolamide zur behandlung von hiv-infektionen
HK1063781B (en) Pyrazole derivatives for treating hiv

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted